Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of cancer.

Allinson SL.

Future Oncol. 2010 Jun;6(6):1031-42. doi: 10.2217/fon.10.40.

PMID:
20528239
2.

Polynucleotide kinase as a potential target for enhancing cytotoxicity by ionizing radiation and topoisomerase I inhibitors.

Bernstein NK, Karimi-Busheri F, Rasouli-Nia A, Mani R, Dianov G, Glover JN, Weinfeld M.

Anticancer Agents Med Chem. 2008 May;8(4):358-67. Review.

3.

Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.

Freschauf GK, Mani RS, Mereniuk TR, Fanta M, Virgen CA, Dianov GL, Grassot JM, Hall DG, Weinfeld M.

J Biol Chem. 2010 Jan 22;285(4):2351-60. doi: 10.1074/jbc.M109.055764. Epub 2009 Nov 23.

4.

Human polynucleotide kinase participates in repair of DNA double-strand breaks by nonhomologous end joining but not homologous recombination.

Karimi-Busheri F, Rasouli-Nia A, Allalunis-Turner J, Weinfeld M.

Cancer Res. 2007 Jul 15;67(14):6619-25.

5.

Cadmium and copper inhibit both DNA repair activities of polynucleotide kinase.

Whiteside JR, Box CL, McMillan TJ, Allinson SL.

DNA Repair (Amst). 2010 Jan 2;9(1):83-9. doi: 10.1016/j.dnarep.2009.11.004. Epub 2009 Dec 3.

PMID:
19962355
6.

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

Ashworth A.

J Clin Oncol. 2008 Aug 1;26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. Epub 2008 Jun 30. Review.

PMID:
18591545
7.

Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.

Chalmers AJ, Lakshman M, Chan N, Bristow RG.

Semin Radiat Oncol. 2010 Oct;20(4):274-81. doi: 10.1016/j.semradonc.2010.06.001. Review.

PMID:
20832020
8.

Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase.

Freschauf GK, Karimi-Busheri F, Ulaczyk-Lesanko A, Mereniuk TR, Ahrens A, Koshy JM, Rasouli-Nia A, Pasarj P, Holmes CF, Rininsland F, Hall DG, Weinfeld M.

Cancer Res. 2009 Oct 1;69(19):7739-46. doi: 10.1158/0008-5472.CAN-09-1805. Epub 2009 Sep 22.

9.

Non-homologous DNA end joining in anticancer therapy.

Pastwa E, Malinowski M.

Curr Cancer Drug Targets. 2007 May;7(3):243-50. Review.

PMID:
17504121
10.

The molecular architecture of the mammalian DNA repair enzyme, polynucleotide kinase.

Bernstein NK, Williams RS, Rakovszky ML, Cui D, Green R, Karimi-Busheri F, Mani RS, Galicia S, Koch CA, Cass CE, Durocher D, Weinfeld M, Glover JN.

Mol Cell. 2005 Mar 4;17(5):657-70.

11.

Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors.

Weingeist DM, Ge J, Wood DK, Mutamba JT, Huang Q, Rowland EA, Yaffe MB, Floyd S, Engelward BP.

Cell Cycle. 2013 Mar 15;12(6):907-15. doi: 10.4161/cc.23880. Epub 2013 Feb 19.

12.

The structural basis for substrate recognition by mammalian polynucleotide kinase 3' phosphatase.

Garces F, Pearl LH, Oliver AW.

Mol Cell. 2011 Nov 4;44(3):385-96. doi: 10.1016/j.molcel.2011.08.036.

13.
14.

Involvement of human polynucleotide kinase in double-strand break repair by non-homologous end joining.

Chappell C, Hanakahi LA, Karimi-Busheri F, Weinfeld M, West SC.

EMBO J. 2002 Jun 3;21(11):2827-32.

15.

Sensitive and rapid screening of T4 polynucleotide kinase activity and inhibition based on coupled exonuclease reaction and graphene oxide platform.

Lin L, Liu Y, Zhao X, Li J.

Anal Chem. 2011 Nov 15;83(22):8396-402. doi: 10.1021/ac200593g. Epub 2011 Oct 25.

PMID:
22026510
16.

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, Chen CS.

Cancer Res. 2007 Jun 1;67(11):5318-27.

17.
18.

Pnk1, a DNA kinase/phosphatase required for normal response to DNA damage by gamma-radiation or camptothecin in Schizosaccharomyces pombe.

Meijer M, Karimi-Busheri F, Huang TY, Weinfeld M, Young D.

J Biol Chem. 2002 Feb 8;277(6):4050-5. Epub 2001 Nov 29.

19.

XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair.

Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, Weinfeld M, Caldecott KW.

Cell. 2001 Jan 12;104(1):107-17.

20.

[PARP inhibitors--theoretical basis and clinical application].

Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.

Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk